Key result
Pulmonary delivery of AF drugs provides rapid onset at very low doses, reducing dose-related adverse effects.
Why the study?
Current oral and intravenous pharmacological treatments for AF have major limitations, including slow onset of action, need for hospitalization, high doses, and frequent dose-related adverse effects.
Does pulmonary delivery of drugs improve the management of atrial fibrillation compared to oral or intravenous routes?
Does pulmonary delivery of drugs improve the management of atrial fibrillation compared to oral or intravenous routes?
Pulmonary delivery of anti-arrhythmic drugs represents a promising novel approach for atrial fibrillation management, potentially offering rapid onset and lower systemic toxicity.
May support pulmonary AF drug delivery; leaves open randomized confirmation before practice change.
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, affecting approximately 335 million patients worldwide. Comprehensive pharmacological treatment of AF includes medications for rate or rhythm control and anticoagulants to reduce the risk of thromboembolism; yet, these agents have significant limitations. Oral anti-arrhythmic agents have a slow onset of action, and rapid onset formulations require hospitalization for intravenous therapy. Orally administered drugs also require high doses to attain therapeutic levels, and thus dose-related severe adverse effects are often unavoidable. Given the therapeutic benefits of inhaled drug delivery, including rapid onset of action and very low doses to achieve therapeutic efficacy, this review will discuss the benefits of novel pulmonary delivery of drugs for the management of AF.
No takes yet. Share an insight, caveat, or question.
Islam et al. (2022) conducted a review in Atrial Fibrillation. Pulmonary drug delivery (inhaled antiarrhythmics and anticoagulants) vs. Oral and intravenous drug delivery was evaluated. Pulmonary delivery of drugs for atrial fibrillation provides rapid onset of action and effective therapeutic benefits at very low doses, significantly reducing dose-related adverse effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: